Cancer Advisor

Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...

Executive Summary : As nutritional oncology shifts focus from isolated "superfoods" to systemic metabolic frameworks, this comprehensive briefing reviews the current clinical consensus, structural dietary guidelines, and the rising counter-culture of repurposed therapies in 2026. 1. The Shift in Nutritional Oncology: Systems Over Components In 2026, the intersection of oncology and nutritional science has definitively moved away from reductive "magic bullet" nutrients. Following the latest updates to global dietary guidelines, the clinical community emphasizes systemic dietary architecture. Rather than evaluating isolated antioxidants, researchers are tracking how complete dietary patterns modulate systemic inflammation, insulin-like growth factors (IGF-1), and the gut microbiome to alter the host environment's receptivity to oncogenesis.  Source: American Institute for Cancer Research ...